Molecular biology tools company Zymo Research said on Tuesday that it plans to introduce its ready-to-go processing solution to streamline viral DNA/RNA extraction from nasopharyngeal swabs, oropharyngeal swabs, saliva, sputum, plasma and serum, in partnership with Tecan.
The DreamPrep NAP workstation, which features Zymo Research's Quick-DNA/RNA Viral MagBead Kit, provides pre-loaded scripts and optimized for viral RNA extraction, which are currently being validated for COVID-19 assays by high complexity testing labs.
Zymo's DreamPrep NAP workstation workflows require time-consuming scripting, configuration and optimization for the nucleic acid extraction to function properly, which can dramatically decrease lab scalability in this critical time.
In addition, the preprogrammed, preconfigured, load-and-go system is optimized for high-throughput viral RNA extraction. The workstation features a user-friendly interface and guided setup to streamline implementation, concluded the partnership.
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD